Lead sponsor
Shanghai Fengxian District Central Hospital
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
0
Active
15
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep ApneaBMI ≥27not applicableCompleted15